The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond
Recent years have brought major advancements in the use of immune therapy and specifically immune checkpoint inhibitors (ICIs) in cancer patients, with expanding indications for various malignancies resulting in the treatment of a large and increasing number of patients. While this therapy significa...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/2/304 |
| _version_ | 1797476107658723328 |
|---|---|
| author | Dan Gilon Zaza Iakobishvili David Leibowitz |
| author_facet | Dan Gilon Zaza Iakobishvili David Leibowitz |
| author_sort | Dan Gilon |
| collection | DOAJ |
| description | Recent years have brought major advancements in the use of immune therapy and specifically immune checkpoint inhibitors (ICIs) in cancer patients, with expanding indications for various malignancies resulting in the treatment of a large and increasing number of patients. While this therapy significantly improves outcomes in a variety of hematologic and solid tumors, the use of ICIs is associated with a substantial risk of immune-related adverse events. Cardiovascular toxicity, while not the most common side effect of ICIs, is associated with significant morbidity and mortality. It is therefore crucial for oncologists and cardiologists, as well as internists and emergency room physicians, to have a good understanding of this increasingly common clinical problem. In the present review, we discuss the cardiac aspects of ICI therapy with special emphasis on the clinical manifestations of their cardiovascular toxicity, diagnostic approaches, treatment and suggested surveillance. |
| first_indexed | 2024-03-09T20:53:17Z |
| format | Article |
| id | doaj.art-2c0c523d249b4c318a0d543847709740 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T20:53:17Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-2c0c523d249b4c318a0d5438477097402023-11-23T22:26:53ZengMDPI AGVaccines2076-393X2022-02-0110230410.3390/vaccines10020304The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and BeyondDan Gilon0Zaza Iakobishvili1David Leibowitz2Cardio-Oncology, Heart Institute, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112001, IsraelDepartment of Cardiology, Clalit Health Services, Tel Aviv District, Holon 5840608, IsraelCardio-Oncology, Heart Institute, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112001, IsraelRecent years have brought major advancements in the use of immune therapy and specifically immune checkpoint inhibitors (ICIs) in cancer patients, with expanding indications for various malignancies resulting in the treatment of a large and increasing number of patients. While this therapy significantly improves outcomes in a variety of hematologic and solid tumors, the use of ICIs is associated with a substantial risk of immune-related adverse events. Cardiovascular toxicity, while not the most common side effect of ICIs, is associated with significant morbidity and mortality. It is therefore crucial for oncologists and cardiologists, as well as internists and emergency room physicians, to have a good understanding of this increasingly common clinical problem. In the present review, we discuss the cardiac aspects of ICI therapy with special emphasis on the clinical manifestations of their cardiovascular toxicity, diagnostic approaches, treatment and suggested surveillance.https://www.mdpi.com/2076-393X/10/2/304immune therapyimmune checkpoint inhibitorscancercardiovascular toxicitymyocarditis |
| spellingShingle | Dan Gilon Zaza Iakobishvili David Leibowitz The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond Vaccines immune therapy immune checkpoint inhibitors cancer cardiovascular toxicity myocarditis |
| title | The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond |
| title_full | The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond |
| title_fullStr | The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond |
| title_full_unstemmed | The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond |
| title_short | The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond |
| title_sort | diagnosis and management of immune checkpoint inhibitor cardiovascular toxicity myocarditis and beyond |
| topic | immune therapy immune checkpoint inhibitors cancer cardiovascular toxicity myocarditis |
| url | https://www.mdpi.com/2076-393X/10/2/304 |
| work_keys_str_mv | AT dangilon thediagnosisandmanagementofimmunecheckpointinhibitorcardiovasculartoxicitymyocarditisandbeyond AT zazaiakobishvili thediagnosisandmanagementofimmunecheckpointinhibitorcardiovasculartoxicitymyocarditisandbeyond AT davidleibowitz thediagnosisandmanagementofimmunecheckpointinhibitorcardiovasculartoxicitymyocarditisandbeyond AT dangilon diagnosisandmanagementofimmunecheckpointinhibitorcardiovasculartoxicitymyocarditisandbeyond AT zazaiakobishvili diagnosisandmanagementofimmunecheckpointinhibitorcardiovasculartoxicitymyocarditisandbeyond AT davidleibowitz diagnosisandmanagementofimmunecheckpointinhibitorcardiovasculartoxicitymyocarditisandbeyond |